Bachem Holding AG stock (CH0012530207): peptide specialist in focus after latest business update

Bachem Holding AG remains in the spotlight after its recent business update and ongoing expansion in peptide and oligonucleotide manufacturing. What drives the Swiss biotech supplier’s story, and why could it matter for internationally oriented US investors?

Bachem Holding AG, the Swiss specialist for peptides and related active pharmaceutical ingredients, has remained in focus after its recent business update on 2024 performance and ongoing capacity expansion in Europe and the US. The group highlighted demand trends in its custom synthesis and generic APIs business, according to a business update published on 03/19/2025 on its investor website, as reported by Bachem investor relations as of 03/19/2025.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bachem
• Sector/industry: Pharmaceuticals, biotech contract manufacturing
• Headquarters/country: Bubendorf, Switzerland
• Core markets: Europe, North America, selected Asian markets
• Key revenue drivers: Custom and generic peptide APIs, oligonucleotide manufacturing, research-grade peptides
• Home exchange/listing venue: SIX Swiss Exchange (ticker: BANB)
• Trading currency: Swiss franc (CHF)

Bachem Holding AG: core business model

Bachem Holding AG is a vertically integrated manufacturer of peptides and related active pharmaceutical ingredients, supplying pharmaceutical and biotech customers worldwide. The company operates as a contract development and manufacturing organization, or CDMO, providing both custom synthesis and catalog products for research and commercial use, according to its corporate profile dated 2024 on the company website, as noted by Bachem company information as of 2024.

The business is organized around large-scale production of peptide APIs for approved drugs, development and manufacturing services for molecules in clinical pipelines, and a range of research-grade peptides serving laboratories and diagnostic firms. This mix gives Bachem exposure to both recurring commercial volumes and project-based development revenues, which can fluctuate with customer pipelines and regulatory milestones in the biopharma industry.

In recent years, Bachem has also been expanding into oligonucleotides, a class of nucleic acid–based therapeutics that includes antisense and RNA-based drugs. Management has described oligonucleotides as a strategic extension of its peptide expertise and chemistry platform, with the goal of becoming a significant supplier in this fast-growing modality, according to presentations published in 2023 and 2024 on its investor site, as cited by Bachem reports and presentations as of 2024.

Main revenue and product drivers for Bachem Holding AG

Bachem’s revenue base is anchored in peptide APIs for approved drugs and late-stage clinical candidates. Demand for these products is highly linked to prescription trends, new drug approvals, and the success of biopharma pipelines. The company reported that peptides for metabolic and oncology indications represent key revenue contributors, according to its annual report for the 2023 financial year, published on 03/14/2024, as summarized by Bachem financial reports as of 03/14/2024.

Long-term supply agreements with pharmaceutical partners help underpin utilization of Bachem’s large-scale production facilities. At the same time, the development services business, which includes process development, scale-up, and clinical manufacturing, tends to be more project-driven. This can introduce volatility from year to year, but also offers upside when customers move candidates swiftly through late-stage trials and into commercialization.

The strategic push into oligonucleotides is another potential growth driver. As more RNA-based therapies advance in clinical development, specialized manufacturing capacity is needed to meet stringent quality and regulatory requirements. Bachem has invested in facilities and capabilities targeting this segment, aiming to position itself as a long-term partner for biotech and pharma clients that lack in-house large-scale manufacturing expertise, as highlighted in its capital markets materials in 2023 and 2024, referenced by Bachem presentations as of 2024.

Why Bachem Holding AG matters for US investors

Even though Bachem is listed on the SIX Swiss Exchange and reports in Swiss francs, its customer base and pipeline exposure extend deep into the US biotech and pharmaceutical ecosystem. Many of its clients are based in the United States or conduct a large share of their clinical development and commercialization activities there, according to statements in its 2023 annual report published on 03/14/2024, as covered by Bachem financial reports as of 03/14/2024.

For US investors seeking diversified exposure to the broader biotech development cycle without owning individual clinical-stage companies, a contract manufacturer such as Bachem can offer an indirect play on peptide and oligonucleotide pipelines. Revenues are typically tied to a portfolio of molecules across different partners and indications, which can spread risk compared with single-product biotechs whose valuations may hinge on one or two key trials.

At the same time, US-based institutional investors often monitor capacity expansions and regulatory developments at suppliers like Bachem as a signal for the health of the broader peptide and RNA-therapeutics markets. Shifts in US drug pricing, reimbursement frameworks, and FDA approval activity can feed back into demand for outsourced manufacturing services, making Bachem’s updates relevant beyond the Swiss equity market.

Conclusion

Bachem Holding AG occupies a specialized position at the intersection of pharmaceutical outsourcing, peptide chemistry, and emerging oligonucleotide therapeutics. Its role as a CDMO exposes it to a broad set of partners and pipeline candidates, while also requiring sustained investment in capacity, quality systems, and talent across Europe and North America. For internationally oriented US investors, the stock represents an indirect way to follow developments in peptide- and RNA-based drugs, but also comes with currency, regulatory, and capacity-utilization risks that warrant close monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.